1. Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects
2. Gathe, J.; Cade, J.; DeJesus, E.; Feinberg, J.; Lalezari, J.; Morales-Ramírez, J. O.; Scarsella, A.; Saag, M.; Thompson, M.; Lefebvre, E.Week-24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with Emtricitabine/Tenofovir, in Treatment-naïve HIV-1+ Adults with CCR5-tropic Virus. Presented at 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, 2013.
3. Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen
4. Mathias, A. A.; Menning, M. M.; Wei, X.; Dave, A.; Chuck, S.; Kearney, B. P.Bioequivalence of the Co-formulation of Emtricitabine/Rilpivirine/Tenofovir DF. Presented at XVIII International AIDS Conference, Vienna, Austria, July 2010.